

Joseph Gligorov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7133564/joseph-gligorov-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

4,960
citations

35
h-index

66
g-index

266
ext. papers

6,353
ext. citations

4
avg, IF

5.23
L-index

#	Paper	IF	Citations
180	Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Associ [™] la Grosse) network.. <i>Breast</i> , 2022 , 61, 168-174	3.6	1
179	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 1475-1495	10.3	59
178	Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associ [™] La Grosse) network. <i>Acta Oncologica</i> , 2021 , 1-7	3.2	0
177	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021 , 146, 30-47	7.5	15
176	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 197, 113968	3.5	4
175	Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
174	Predicting the likelihood of recurrence of pregnancy-associated breast cancer: Nomogram based on analysis of the French cancer network: Cancer Associ [™] La Grosse. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021 , 50, 101766	1.9	1
173	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 34-41	13.4	30
172	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. <i>Future Oncology</i> , 2021 , 17, 151-157	3.6	1
171	Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. <i>Breast</i> , 2021 , 55, 79-90	3.6	5
170	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 994-1004	10.3	87
169	Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. <i>Annals of Oncology</i> , 2021 , 32, 1051-1053	10.3	38
168	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
167	Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	1
166	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102225	14.4	2
165	High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers. <i>Annals of Oncology</i> , 2021 , 32, 1294-1295	10.3	21
164	1773P Mainstreamed genetic testing for French breast and ovarian cancer patients and its utility during the COVID-19 pandemic. <i>Annals of Oncology</i> , 2020 , 31, S1028	10.3	78

163	A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. <i>European Journal of Cancer</i> , 2020 , 135, 130-146	7.5	22
162	Severe acute respiratory syndrome Coronavirus 2 infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible?. <i>International Journal of Cancer</i> , 2020 , 147, 3576-3578	7.5	
161	Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?. <i>European Journal of Cancer</i> , 2020 , 136, 1-3	7.5	3
160	Creating Synthetic Patients to Address Interoperability Issues: A Case Study with the Management of Breast Cancer Patients. <i>Studies in Health Technology and Informatics</i> , 2020 , 275, 177-181	0.5	1
159	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1007-1007	2.2	24
158	An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. <i>PLoS ONE</i> , 2020 , 15, e0227356	3.7	6
157	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649	10.3	282
156	Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. <i>European Journal of Medical Genetics</i> , 2020 , 63, 104098	2.6	3
155	LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) + atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). <i>Annals of Oncology</i> , 2020 , 31, S1147-S1148	10.3	50
154	Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associ ^m La Grossesse) network. <i>Breast</i> , 2020 , 54, 311-318	3.6	2
153	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
152	Percutaneous Image-Guided Electrochemotherapy of Spine Metastases: Initial Experience. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1806-1809	2.7	13
151	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 383-393	4.4	10
150	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. <i>Lancet, The</i> , 2019 , 393, 2591-2598	4.0	52
149	Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial. <i>Annals of Oncology</i> , 2019 , 30, v141	10.3	2
148	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an pro and con discussion. <i>ESMO Open</i> , 2019 , 4, e000565	6	6
147	Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial 2019 ,		15
146	STANDARDS OF CARE AND OPTIMAL OPTIONS FOR LUMINAL ABC. <i>Breast</i> , 2019 , 48, S27-S28	3.6	

145	The extracellular domain of Her2 in serum as a biomarker of breast cancer. <i>Laboratory Investigation</i> , 2018 , 98, 696-707	5.9	35
144	Propensity score to evaluate prognosis in pregnancy-associated breast cancer: Analysis from a French cancer network. <i>Breast</i> , 2018 , 40, 10-15	3.6	12
143	The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 95-113	3	32
142	High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). <i>Clinical Cancer Research</i> , 2018 , 24, 3053-3058	12.9	11
141	Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. <i>Oncologist</i> , 2018 , 23, 1137-1143	5.7	11
140	Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes. <i>Frontiers in Oncology</i> , 2018 , 8, 112	5.3	14
139	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. <i>European Journal of Human Genetics</i> , 2018 , 26, 1732-1742	5.3	23
138	Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) 2018 ,		3
137	Early HER2-positive breast cancers: time for a new revolution?. <i>Lancet Oncology, The</i> , 2018 , 19, 12-13	21.7	1
136	Citrate targets FBPAse and constitutes an emerging novel approach for cancer therapy. <i>Cancer Cell International</i> , 2018 , 18, 175	6.4	5
135	Patients with delirium and advanced solid cancer in the emergency department: A challenge for the emergency practitioner, oncologist, and intensivist. <i>Cancer</i> , 2017 , 123, 704-705	6.4	1
134	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
133	Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. <i>Breast</i> , 2017 , 34, 89-95	3.6	13
132	Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017 , 32, 247-255	3.6	9
131	Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. <i>European Journal of Cancer</i> , 2017 , 86, 82-90	7.5	33
130	Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. <i>Cancer Medicine</i> , 2017 , 6, 2732-2744	4.8	19
129	IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC). <i>Annals of Oncology</i> , 2017 , 28, v105	10.3	4
128	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. <i>Journal of Onco-Nephrology</i> , 2017 , 1, 213-219	0.2	

127	Câncer de mama inflamatorio. <i>EMC - Ginecología-Obstetricia</i> , 2017 , 53, 1-9	0	
126	Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. <i>European Journal of Cancer</i> , 2017 , 81, 151-160	7.5	3
125	Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetasPHer study. <i>European Journal of Cancer</i> , 2017 , 82, 230-236	7.5	32
124	Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study. <i>Clinical Breast Cancer</i> , 2017 , 17, 107-116	3	1
123	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017 , 28, 103-109	10.3	40
122	Breast cancer metastasis to the spleen: a case report and literature review. <i>Oxford Medical Case Reports</i> , 2017 , 2017, omx069	0.6	5
121	Long-term complete response in a breast cancer patient with skeletal muscle metastases diagnosed using 18F-FDG-PET. <i>Oxford Medical Case Reports</i> , 2017 , 2017, omx002	0.6	4
120	Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study) 2017 ,		2
119	Efficacy of epirubicin-paclitaxel (EPI-TAX) prior to high-dose chemotherapy (HDCT) in germ cell tumors (GCTs): A 17-year experience.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4557-4557	2.2	1
118	Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. <i>Annals of Oncology</i> , 2016 , 27, 2046-2052	10.3	26
117	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. <i>SpringerPlus</i> , 2016 , 5, 45		12
116	A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. <i>Chemotherapy</i> , 2016 , 61, 15-22	3.2	1
115	A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS625-TPS625	2.2	1
114	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40	3.3	31
113	Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 603-603	2.2	
112	Incidence and Risk Factors for Central Venous Catheter-Related Venous Thromboembolism in Breast Cancer Patients Under Neoadjuvant Chemotherapy: the Caveccas (Catheter Veineux Central et Cancer du Sein) Study. <i>Blood</i> , 2016 , 128, 2607-2607	2.2	
111	Pertuzumab and trastuzumab: the rationale way to synergy. <i>Anais Da Academia Brasileira De Ciencias</i> , 2016 , 88 Suppl 1, 565-77	1.4	31
110	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016 , 6, S1-S10		7

109	Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. <i>European Journal of Cancer</i> , 2016 , <i>56</i> , 104-13	7.5	43
108	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. <i>Oncologist</i> , 2015 , <i>20</i> , 873-9	5.7	33
107	Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC. <i>Nature Reviews Clinical Oncology</i> , 2015 , <i>12</i> , 508-9	19.4	14
106	Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015 , <i>19</i> , 295-302	1.3	8
105	Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. <i>Brazilian Journal of Medical and Biological Research</i> , 2015 , <i>48</i> , 13-24	2.8	6
104	Looking for predictive markers in breast cancer--authors' reply. <i>Lancet Oncology, The</i> , 2015 , <i>16</i> , e1-2	21.7	
103	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014 , <i>23</i> , 489-502	3.6	231
102	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , <i>15</i> , 1028-38	21.7	103
101	A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. <i>Annals of Oncology</i> , 2014 , <i>25</i> , 1775-1782	10.3	19
100	Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. <i>Annals of Oncology</i> , 2014 , <i>25</i> , 1570-7	10.3	75
99	Chimiothérapie des tumeurs trophoblastiques gestationnelles à haut risque. <i>Oncologie</i> , 2014 , <i>16</i> , 291-299		1
98	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , <i>15</i> , 1351-60	21.7	102
97	Une première collaboration entre Oncologie et la Fédération Française de Cancérologie Digestive (FFCD) !. <i>Oncologie</i> , 2014 , <i>16</i> , 483-483		1
96	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Annals of Oncology, 2014 , <i>25</i> , 1871-1888	10.3	279
95	Le privilège d'une spécialité en mouvement. <i>Oncologie</i> , 2014 , <i>16</i> , 1-2		1
94	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014 , <i>25</i> , 1979-1987	10.3	101
93	Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013 , <i>139</i> , 421-8	4.4	15
92	HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , <i>88</i> , 123-33	7	14

91	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 437-46	4.4	56
90	Juste dix ans. <i>Oncologie</i> , 2013 , 15, 565-566	1	1
89	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. <i>Lancet Oncology</i> , 2013 , 14, 962-70	21.7	143
88	Modification du métabolisme tumoral au cours du traitement : suivi de la réponse thérapeutique par tomographie par émission de positons. <i>Oncologie</i> , 2013 , 15, 448-453	1	
87	Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?. <i>British Journal of Cancer</i> , 2013 , 109, 1147-56	8.7	15
86	Acute kidney failure with renal carcinomatous lymphangitis secondary to advanced colon cancer. <i>Kidney International</i> , 2013 , 84, 420	9.9	1
85	Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study 2013 ,		3
84	Critères de choix d'une chimiothérapie néoadjuvante 2013 , 92-112		
83	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012 , 21, 20-6	3.6	24
82	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012 , 21, 242-52	3.6	258
81	Pregnancy-associated breast cancers: do they differ from other breast cancers in young women?. <i>Breast</i> , 2012 , 21, 550-5	3.6	49
80	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. <i>Lancet Oncology</i> , 2012 , 13, 375-84	21.7	134
79	Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. <i>Journal of Medical Economics</i> , 2012 , 15, 1167-75	2.4	8
78	Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC). <i>Annals of Oncology</i> , 2012 , 23, ix114-ix115	10.3	4
77	Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 601-7	4.4	12
76	Adjuvant treatments for triple-negative breast cancers. <i>Annals of Oncology</i> , 2012 , 23 Suppl 6, vi40-5	10.3	79
75	Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. <i>Oncologist</i> , 2012 , 17, 469-75	5.7	39
74	Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 568-568	2.2	6

73	Optimisation du nomogramme de réponse à la chimiothérapie néoadjuvante du MDACC pour un schéma utilisant plus de 4 cycles d'anthracycline 2012 , 358-359		1
72	Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. <i>European Journal of Cancer</i> , 2011 , 47, 2396-402	7.5	12
71	Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival. <i>Clinical Breast Cancer</i> , 2011 , 11, 46-51	3	8
70	Candidoses oropharyngées (COP) et cancers solides. <i>Oncologie</i> , 2011 , 13, 167-174	1	
69	4e Recommandations pour la pratique clinique de Nice-St-Paul-de-Vence. <i>Oncologie</i> , 2011 , 13, 605-607	1	
68	Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 532-9	4	24
67	Femmes à haut risque de cancer mammaire: vers des unités et réseaux de surveillance. <i>Imagerie De La Femme</i> , 2011 , 21, 3-11	0.1	
66	Radiotherapy for invasive breast cancer: guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 91-102	7	36
65	Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2011 , 22, 321-8	10.3	13
64	Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e454-5; author reply e456-7	2.2	2
63	Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. <i>Annals of Oncology</i> , 2011 , 22, 1582-1587	10.3	21
62	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. <i>British Journal of Cancer</i> , 2010 , 103, 560-6	8.7	28
61	Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. <i>Oncologist</i> , 2010 , 15, 1169-78	5.7	18
60	Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1825-36	3.5	3
59	First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3lg) enhances immune responses and antitumor activity. <i>Journal of Translational Medicine</i> , 2010 , 8, 71	8.5	164
58	Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge". <i>Radiotherapy and Oncology</i> , 2010 , 94, 119-20; author reply 120-1	5.3	4
57	Pourquoi il est urgent de renforcer l'oncologie médicale. <i>Oncologie</i> , 2010 , 12, 115-116	1	
56	Estramustine : quelle place en 2010 dans le cancer du sein métastatique ?. <i>Oncologie</i> , 2010 , 12, 341-348	1	0

55	Détermination de HER2 dans les adhéocarcinomes pour établir le pronostic et prédire la réponse aux traitements. <i>Oncologie</i> , 2010 , 12, 416-421	1	
54	Connaissances et progrès. <i>Oncologie</i> , 2010 , 12, 301-302	1	
53	Pronostic et prédiction de la réponse aux traitements par la biologie des cancers: une opportunité pour changer les concepts par l'innovation. <i>Oncologie</i> , 2010 , 12, 383-383	1	
52	Détermination de HER2 dans les adhéocarcinomes pour établir le pronostic et prédire la réponse aux traitements. <i>Bio Tribune Magazine</i> , 2010 , 36, 30-35		
51	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 745-53	4.4	37
50	Pregnancy after breast cancer: a need for global patient care, starting before adjuvant therapy. <i>Surgical Oncology</i> , 2010 , 19, e47-55	2.5	10
49	Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. <i>Surgical Oncology</i> , 2010 , 19, e115-23	2.5	38
48	Drug management of prostate cancer: prevalence and consequences of renal insufficiency. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E83-9	3.3	19
47	Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged . <i>Cancer</i> , 2009 , 115, 5155-65	6.4	44
46	Recherche clinique: gagner la partie d'adhéc. <i>Oncologie</i> , 2009 , 11, 315-316	1	
45	La recherche clinique dans le domaine du cancer du sein: état des lieux et perspectives. <i>Oncologie</i> , 2009 , 11, 319-324	1	
44	L'avenir de l'oncologie médicale française est en danger. <i>Oncologie</i> , 2009 , 11, 311-311	1	
43	Recommandations pour la pratique clinique, Nice, Saint-Paul-de-Vence: et de trois !. <i>Oncologie</i> , 2009 , 11, 495-496	1	4
42	Lung cancer and renal insufficiency: prevalence and anticancer drug issues. <i>Lung</i> , 2009 , 187, 69-74	2.9	34
41	Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 124-33	7	34
40	Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 12-21	7	28
39	Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. <i>Annals of Oncology</i> , 2008 , 19, 1110-6	10.3	79
38	Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 112 Suppl 1, 53-66	4.4	40

37	Cancer du sein m†astatique. <i>Oncologie</i> , 2008 , 10, 136-148	1	1
36	From politics to economics: new deal in cancer war. <i>Oncologie</i> , 2008 , 10, 301-302	1	
35	Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. <i>Cancer</i> , 2007 , 110, 1376-84	6.4	293
34	Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 64, 115-28	7	25
33	Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 64, 198-207	7	75
32	Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 66-72	4	17
31	Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. <i>Breast</i> , 2007 , 16 Suppl 3, S1-9	3.6	10
30	Hormonoradioth†rapie concomitante: application au traitement adjuvant des cancers du sein. <i>Oncologie</i> , 2007 , 9, 466-469	1	
29	Sp†cificit† de la chimioth†rapie chez le sujet g†. <i>Oncologie</i> , 2007 , 9, 783-789	1	
28	Intensit† de dose dans le traitement du cancer du sein. <i>Oncologie</i> , 2007 , 9, 814-820	1	
27	Cancer du sein 2007 ,		2
26	Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2678-84	2.2	105
25	Supporting multidisciplinary staff meetings for guideline-based breast cancer management: a study with OncoDoc2 2007 , 656-60	0.7	5
24	Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies. <i>Targeted Oncology</i> , 2006 , 1, 228-238	5	
23	Cardiovascular safety profiles of aromatase inhibitors : a comparative review. <i>Drug Safety</i> , 2006 , 29, 785-801	3.1	23
22	The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. <i>Reviews on Recent Clinical Trials</i> , 2006 , 1, 237-49	1.2	6
21	Taxane therapy for early stage breast cancer. <i>Women's Health</i> , 2006 , 2, 99-114	3	2
20	Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. <i>Bone Marrow Transplantation</i> , 2006 , 37, 669-75	4.4	5

19	Cancers du Sein M†astatique. <i>Oncologie</i> , 2006 , 8, 36-50	1	1
18	Quoi de neuf docteur?. <i>Oncologie</i> , 2006 , 8, 621-622	1	
17	R†sistances † lâbormonoth†rapie dans le cancer du sein. <i>Oncologie</i> , 2006 , 8, 762-766	1	
16	Modalit†s d†utilisation et apport du trastuzumab en situation adjuvante. <i>Oncologie</i> , 2006 , 8, 748-753	1	
15	Densit†de dose et intensit†de dose dans le traitement adjuvant du cancer du sein 2006 , 437-453		
14	Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1555-64	4	13
13	Docetaxel in the treatment of breast cancer: current experience and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 613-33	3.5	8
12	Y a-t-il une possibilit†qu†court ou moyen terme un d†pistage et une pr†vention du cancer de lâbvaire soient efficaces?. <i>Oncologie</i> , 2005 , 7, 531-536	1	1
11	Du progr†s: d†croire, de le d†montrer et d†avoir acc†. Propos des nouvelles th†rapies en cancfologie. L†exemple du trastuzumab. <i>Oncologie</i> , 2005 , 7, s100-s102	1	
10	Essais cliniques fran†ais en cancfologie. R†ultats du premier recensement. <i>Oncologie</i> , 2005 , 7, s103-s103	1	
9	Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. <i>Clinical Chemistry</i> , 2005 , 51, 1000-101	5.5	78
8	Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicenter TAXIF trial. <i>Annals of Oncology</i> , 2005 , 16, 111-9	10.3	44
7	The role of taxanes in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1073-94	4	34
6	Preclinical pharmacology of the taxanes: implications of the differences. <i>Oncologist</i> , 2004 , 9 Suppl 2, 3-8	5.7	164
5	Actualit†de lâASCO 2004 par localisations. <i>Oncologie</i> , 2004 , 6, 321-323	1	
4	Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. <i>Joint Bone Spine</i> , 2000 , 67, 22-9	2.9	14
3	A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. <i>New England Journal of Medicine</i> , 1999 , 341, 1475-6	59.2	3
2	Genetic abnormalities in synovial sarcoma. <i>New England Journal of Medicine</i> , 1998 , 338, 1699	59.2	

1 Thrombose réversible de l'artère pulmonaire. *Revue De Medecine Interne*, **1995**, 16, 265s-266s

0.1